HC Wainwright Issues Pessimistic Forecast for TLX Earnings

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Analysts at HC Wainwright reduced their FY2026 earnings estimates for Telix Pharmaceuticals in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst R. Burns now expects that the company will earn $0.15 per share for the year, down from their prior estimate of $0.32. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.06). The company had revenue of $414.02 million during the quarter, compared to analysts’ expectations of $421.50 million.

Several other brokerages also recently weighed in on TLX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Citigroup raised their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Stock Performance

NASDAQ:TLX opened at $7.52 on Thursday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.22. The stock’s 50 day simple moving average is $7.41 and its 200-day simple moving average is $9.13. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $20.00.

Institutional Trading of Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. XTX Topco Ltd acquired a new stake in Telix Pharmaceuticals during the fourth quarter worth about $89,000. IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the second quarter worth about $213,000. OLD Mission Capital LLC bought a new position in Telix Pharmaceuticals in the fourth quarter worth about $111,000. Finally, Private Advisor Group LLC boosted its stake in Telix Pharmaceuticals by 67.3% in the third quarter. Private Advisor Group LLC now owns 42,112 shares of the company’s stock valued at $403,000 after acquiring an additional 16,945 shares during the period.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.